Related references
Note: Only part of the references are listed.Acral lentiginous melanoma: Basic facts, biological characteristics and research perspectives of an understudied disease
Patricia Basurto-Lozada et al.
PIGMENT CELL & MELANOMA RESEARCH (2021)
The ongoing racial disparities in melanoma: An analysis of the Surveillance, Epidemiology, and End Results database (1975-2016)
Yingzhi Qian et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma
Xieqiao Yan et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment
S. Byeon et al.
ESMO OPEN (2021)
Frequency of mutations in BRAF, NRAS, and KIT in different populations and histological subtypes of melanoma: a systemic review
Luz Dary Gutierrez-Castaneda et al.
MELANOMA RESEARCH (2020)
Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies
Jie Qian et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Burden of melanoma in China, 1990-2017: Findings from the 2017 global burden of disease study
Yan Wu et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
The mutational landscape of mucosal melanoma
Kelsey W. Nassar et al.
SEMINARS IN CANCER BIOLOGY (2020)
Distinct genomic traits of acral and mucosal melanomas revealed by targeted mutational profiling
Zhengyun Zou et al.
PIGMENT CELL & MELANOMA RESEARCH (2020)
The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma
Xiaoting Wei et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
Acral lentiginous melanoma: clinicopathological characteristics and survival outcomes in theUSNational Cancer Database 2004-2016
S. Behbahani et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial
Bixia Tang et al.
CLINICAL CANCER RESEARCH (2020)
Characterizations of Gene Alterations in Melanoma Patients from Chinese Population
Yi Luo et al.
BIOMED RESEARCH INTERNATIONAL (2020)
A phase II study of vorolanib (CM082) in combination with toripalimab (JS001) in patients with advanced mucosal melanoma.
Lu Si et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Targetable immune checkpoint molecules may be significantly differentially expressed in minority ethnicities.
Jacob J. Adashek et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
CheckMate 067: Long-term outcomes in patients with mucosal melanoma.
Alexander Noor Shoushtari et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
Nicholas D. Klemen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients
Y. Nakamura et al.
ANNALS OF ONCOLOGY (2020)
PD-1 Blockade in Chinese versus Western Patients with Melanoma
Alexander N. Shoushtari et al.
CLINICAL CANCER RESEARCH (2020)
Cutaneous melanoma and the immunotherapy revolution (Review)
Giulia C. Leonardi et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2020)
Molecular gene mutation profiles, TMB and the impact of prognosis in Caucasians and east Asian patients with lung adenocarcinoma
Weiquan Gu et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naive Patients with Diverse Cancers
Paul Riviere et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity
Felicity Newell et al.
NATURE COMMUNICATIONS (2020)
Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas
Jarem Edwards et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients
Franz J. Hilke et al.
CANCERS (2020)
A genomic signature for accurate classification and prediction of clinical outcomes in cancer patients treated with immune checkpoint blockade immunotherapy
Mei Lu et al.
SCIENTIFIC REPORTS (2020)
Melanoma Epidemiology and Sun Exposure
Sara Raimondi et al.
ACTA DERMATO-VENEREOLOGICA (2020)
Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review
Jiarui Li et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
A Functional Synonymous Variant in PDGFRA Is Associated with Better Survival in Acral Melanoma
Jie Dai et al.
JOURNAL OF CANCER (2020)
Relationship between tumor-associated immune infiltrate and p16 staining over clinicopathological features in acral lentiginous melanoma
C. A. Castaneda et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2019)
A study of the clinical characteristics and prognosis of advanced mucosal and cutaneous melanoma in a Chinese population
Yong Zhang et al.
IMMUNOTHERAPY (2019)
Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy
Longwen Xu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert et al.
LANCET ONCOLOGY (2019)
A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)
Lu Si et al.
TRANSLATIONAL ONCOLOGY (2019)
Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets
Felicity Newel et al.
NATURE COMMUNICATIONS (2019)
Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody
Jiyun Lee et al.
BMC CANCER (2019)
Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma
Jiayi Yu et al.
CLINICAL CANCER RESEARCH (2019)
Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial
Xinan Sheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Atypical BRAF and NRAS Mutations in Mucosal Melanoma
Nicolas Dumaz et al.
CANCERS (2019)
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)
Dirk Schadendorf et al.
EUROPEAN JOURNAL OF CANCER (2019)
Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities
Roy Rabbie et al.
JOURNAL OF PATHOLOGY (2019)
Current controversies in early-stage melanoma Questions on incidence, screening, and histologic regression
Laura J. Gardner et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
David Liu et al.
NATURE MEDICINE (2019)
Inhibition of p53 inhibitors: progress, challenges and perspectives
Gema Sanz et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2019)
MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK Pathways
Meng Ma et al.
THERANOSTICS (2019)
Phase Ib/II trial of lenvatinib plus pembrolizumab in advanced melanoma.
Matthew H. Taylor et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Emerging biomarkers for cancer immunotherapy in melanoma
Margaret L. Axelrod et al.
SEMINARS IN CANCER BIOLOGY (2018)
Prognostic factors for metastasis in cutaneous melanoma
Ana Carolina Figueiredo Pereira Cherobin et al.
ANAIS BRASILEIROS DE DERMATOLOGIA (2018)
Multifactorial Analysis of Prognostic Factors and Survival Rates Among 706 Mucosal Melanoma Patients
ChuanLiang Cui et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro
Xiaowen Wu et al.
CANCER BIOLOGY & THERAPY (2018)
Clinical Development of PD-1 in Advanced Melanoma
Rodrigo Ramella Munhoz et al.
CANCER JOURNAL (2018)
CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naive Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment
Jarem Edwards et al.
CLINICAL CANCER RESEARCH (2018)
Clinicopathologic characteristics and survival outcomes of primary mucosal melanomas: A 10-year retrospective analysis from a single tertiary medical center in Thailand
Kumpol Aiempanakit et al.
DERMATOLOGICA SINICA (2018)
Clinicopathological characteristics of malignant melanomas of the skin and gastrointestinal tract
Michiko Akiyama et al.
ONCOLOGY LETTERS (2018)
Immunotherapy in mucosal melanoma: a case report and review of the literature
Hana Studentova et al.
Oncotarget (2018)
Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006
Omid Hamid et al.
BRITISH JOURNAL OF CANCER (2018)
Effect of RNAi-based β-catenin inhibition on immunosuppressive Wnt- activated tumors in combination with IDOi/PD-1 immunotherapy
Shanthi Ganesh et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A phase Ib study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) combination with axitinib in patients with metastatic mucosal melanoma
Jun Guo et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
1270PEfficacy of immunotherapy in patients with metastatic mucosal or uveal melanoma
C Mignard et al.
ANNALS OF ONCOLOGY (2018)
Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study
Kenjiro Namikawa et al.
EUROPEAN JOURNAL OF CANCER (2018)
Combatting mucosal melanoma: recent advances and future perspectives
Helen Tyrrell et al.
MELANOMA MANAGEMENT (2018)
Screening for malignant melanoma-a critical assessment in historical perspective
Wolfgang Weyers
DERMATOLOGY PRACTICAL & CONCEPTUAL (2018)
Treatment and outcomes of melanoma in Asia: Results from the National Cancer Centre Singapore
Yi Lin Teh et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2018)
The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients
B. Lian et al.
ANNALS OF ONCOLOGY (2017)
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
Sandra P. D'Angelo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Mucosal melanomas in the racially diverse population of California
Lisa Altieri et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Impact of skin cancer screening and secondary prevention campaigns on skin cancer incidence and mortality: A systematic review
Alicia Brunssen et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Melanoma subtypes demonstrate distinct PD-L1 expression profiles
Genevieve J. Kaunitz et al.
LABORATORY INVESTIGATION (2017)
Clinics, prognosis and new therapeutic options in patients with mucosal melanoma A retrospective analysis of 75 patients
Tim Schaefer et al.
MEDICINE (2017)
Whole-genome landscapes of major melanoma subtypes
Nicholas K. Hayward et al.
NATURE (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Fluorescence in situ hybridisation as an ancillary tool in the diagnosis of acral melanoma: a review of 44 cases
Jing Su et al.
PATHOLOGY (2017)
Paracrine wnt-beta-catenin signaling inhibition as a strategy to enhance the efficacy of anti-PD-1 antibody (Ab) therapy in a transgenic model of melanoma.
Nicholas C. DeVito et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America
C. A. Castaneda et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2017)
Sunrise inmelanomamanagement: Time to focus onmelanoma burden in Asia
John Wen-Cheng Chang et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2017)
MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases
Xue Bai et al.
CLINICAL CANCER RESEARCH (2017)
Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy
Yan Kong et al.
CLINICAL CANCER RESEARCH (2017)
Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors
Yan Kong et al.
CLINICAL CANCER RESEARCH (2016)
Racial differences in six major subtypes of melanoma: descriptive epidemiology
Yu Wang et al.
BMC CANCER (2016)
The Efficacy of Anti-PD-1 Agents in Acral and Mucosal Melanoma
Alexander N. Shoushtari et al.
CANCER (2016)
GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis
Xinan Sheng et al.
EUROPEAN JOURNAL OF CANCER (2016)
Acral Melanoma in Chinese: A Clinicopathological and Prognostic Study of 142 cases
Jiaojie Lv et al.
SCIENTIFIC REPORTS (2016)
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition
Richard D. Carvajal et al.
CLINICAL CANCER RESEARCH (2015)
Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients
Kaori Sakaizawa et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2015)
Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
Lisa Zimmer et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Characterization of KIT mutation in melanoma
Chi-Yuan Tzen et al.
DERMATOLOGICA SINICA (2014)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Social Determinants of Racial and Ethnic Disparities in Cutaneous Melanoma Outcomes
Valerie M. Harvey et al.
CANCER CONTROL (2014)
Prognosis of Acral Melanoma: A Series of 281 Patients
Danielle M. Bello et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo
S. Yasuda et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2013)
Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma
Bin Lian et al.
CLINICAL CANCER RESEARCH (2013)
Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
Paolo A. Ascierto et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Michael S. Lawrence et al.
NATURE (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
TERT Promoter Mutations in Familial and Sporadic Melanoma
Susanne Horn et al.
SCIENCE (2013)
Highly Recurrent TERT Promoter Mutations in Human Melanoma
Franklin W. Huang et al.
SCIENCE (2013)
The Contribution of Nodular Subtype to Melanoma Mortality in the United States, 1978 to 2007
Waqas R. Shaikh et al.
ARCHIVES OF DERMATOLOGY (2012)
Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort
Lu Si et al.
EUROPEAN JOURNAL OF CANCER (2012)
BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma
Kevin B. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The epidemic' of melanoma between under- and overdiagnosis
Wolfgang Weyers
JOURNAL OF CUTANEOUS PATHOLOGY (2012)
Mucosal Melanoma: A Clinically and Biologically Unique Disease Entity
Richard D. Carvajal et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases
Zhihong Chi et al.
BMC CANCER (2011)
Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma
Yan Kong et al.
CLINICAL CANCER RESEARCH (2011)
Acral Lentiginous Melanoma
Melissa Peck Piliang
CLINICS IN LABORATORY MEDICINE (2011)
A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients
Lili Mao et al.
EUROPEAN JOURNAL OF CANCER (2011)
Dacarbazine-based chemotherapy as first-line treatment in noncutaneous metastatic melanoma: multicenter, retrospective analysis in Asia
Jun Ho Yi et al.
MELANOMA RESEARCH (2011)
A new understanding in the epidemiology of melanoma
Esther Erdei et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2010)
Disparity in Melanoma A Trend Analysis of Melanoma Incidence and Stage at Diagnosis Among Whites, Hispanics, and Blacks in Florida
Shasa Hu et al.
ARCHIVES OF DERMATOLOGY (2009)
Ethnic differences among patients with cutaneous melanoma
Janice N. Cormier et al.
ARCHIVES OF INTERNAL MEDICINE (2006)
Distinct sets of genetic alterations in melanoma
JA Curtin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs
CW Wong et al.
JOURNAL OF CLINICAL PATHOLOGY (2005)
Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit?: A meta-analysis of the randomised trials
K Wheatley et al.
CANCER TREATMENT REVIEWS (2003)
Share Paper
